Inhalations of Ultra-low Doses of Melphalan for the Treatment of Non-cystic Fibrosis Bronchiectasis
Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
This non-randomised open-label prospective pilot study evaluates the safety and efficacy of
inhalations of ultra-low doses of alkylating drug melphalan for the treatment of non-cystic
fibrosis bronchiectasis. All patients will receive 0,1 mg of melphalan in 5 daily inhalations
1 time per day.
Phase:
Phase 2
Details
Lead Sponsor:
Federal State Budgetary Institution, Pulmonology Scientific Research Institute